What is hepatoblastoma, what are its clinical presentation (symptoms), and what are the recommended management strategies?

Hepatoblastoma: Definition, Clinical Presentation, and Management

What is Hepatoblastoma?

Hepatoblastoma is the most common primary malignant liver tumor in children, typically occurring in children under 5 years of age, with peak incidence in the first two years of life 1, 2, 3. While 80% of cases are sporadic, approximately 20% are associated with genetic predisposition syndromes 4.

Associated Genetic Syndromes

The following syndromes significantly increase hepatoblastoma risk:

• Beckwith-Wiedemann syndrome (BWS): Confers a 2,280-fold relative risk 4
• Familial Adenomatous Polyposis (FAP): Risk elevated but <1% for APC mutation carriers 4
• Simpson-Golabi-Behmel syndrome and Sotos syndrome: Rare associations 4
• Constitutional trisomy 18: Associated risk but usually fatal within first 2 years 4
• Metabolic syndromes: Tyrosinemia type I, fumarylacetoacetate hydroxylase deficiency, and glycogen storage diseases predispose to liver tumors 4

Molecular Mechanisms

The key molecular drivers include:

• CTNNB1 gene mutations with activation of the Wnt/β-catenin pathway 1
• Epigenetic mechanisms including DNA methylation and non-coding RNAs 1

---

Clinical Presentation (Symptoms)

The typical presentation is an abdominal mass in a young child, often discovered incidentally or during evaluation for abdominal distension 3. The median age at presentation is approximately 15 months (range 6-36 months) 3.

Key Clinical Features to Assess:

• Abdominal mass or distension: Most common presenting sign
• Prenatal/perinatal complications: In congenital hepatoblastoma (CHB), mortality from "mass effect" occurs in 22% prenatally and 32% perinatally 5
• General condition: Assess if patient is stable enough for proper staging and treatment 5
• Metastatic disease: Presence significantly affects prognosis 6

Important Caveat:

Congenital hepatoblastoma presents unique challenges with significant mortality unrelated to malignancy itself—54% of deaths are due to mass effect rather than oncological factors 5. However, after birth, if patients are stable, CHB does not confer worse oncological prognosis per se 5.

---

Diagnostic Approach

Essential Diagnostic Elements:

1. Serum alpha-fetoprotein (AFP): Elevated in most cases; critical for diagnosis and monitoring 2, 7
2. Imaging studies 2:
   • Ultrasound (initial screening)
   • Computed tomography (CT)
   • Magnetic resonance imaging (MRI)
3. PRETEXT/POST-TEXT staging: Defines extent of disease and surgical approach 6, 8
4. Histological confirmation: Through biopsy when needed 2

Surveillance in High-Risk Syndromes:

For children with BWS and other overgrowth syndromes, implement abdominal ultrasonography every 3 months until age 4, with consideration for periodic AFP measurement every 3 months 4. This surveillance strategy is widely utilized and endorsed by guidelines.

For FAP kindreds, practices vary: many U.S. and Canadian centers screen similarly to overgrowth syndromes, while European centers generally do not recommend screening given the low (<1%) incidence 4.

---

Management Strategy

Multimodal Treatment Algorithm:

The goal of treatment is complete surgical resection, achieved through a risk-based, multimodal approach combining neoadjuvant chemotherapy, surgical resection or liver transplantation, and adjuvant chemotherapy 2, 6, 7, 3.

Step 1: Risk Stratification

Assess based on:

• PRETEXT classification (defines location and extent of disease) 6, 8
• Histologic features 6
• Age at presentation 6
• AFP production 6
• Presence of metastatic disease 6

Step 2: Neoadjuvant Chemotherapy

Most patients (89%) should receive neoadjuvant chemotherapy using cisplatin-based regimens (SIOPEL-1, SIOPEL-3, SIOPEL-4 protocols) for 2-4 cycles 7, 3. This approach:

• Allows significant tumor downstaging 6
• Enables less extensive hepatectomy 6
• Is indicated for moderate-to-high risk of postresection recurrence 6

Exception: Only patients with complete mass excision possible at diagnosis (11%) proceed directly to surgery followed by adjuvant chemotherapy 7.

Step 3: Surgical Decision-Making

The surgical approach depends on PRETEXT staging and tumor resectability after neoadjuvant therapy 8:

Organ-Preserving Resection Options:

• Right hepatectomy: Most common procedure 3
• Left hepatectomy or left lateral hepatectomy 3
• Non-anatomical hepatic resection 3

Criteria for resection: Margin-negative resection must be achievable; success depends on location and extent of disease 6.

Liver Transplantation Indications:

Liver transplantation is appropriate when complete oncological resection requires total hepatectomy or when complete resection is not feasible after neoadjuvant therapy 6, 7. In one series, 34% of patients required transplantation 7.

Critical consideration: The 5-year overall survival is 100% for both transplant and resection patients, though disease-free survival may be lower in transplant patients (75% vs 100%) 7.

Step 4: Adjuvant Chemotherapy

All patients receive adjuvant chemotherapy post-surgery 7, 3.

Step 5: Management of Metastatic/Recurrent Disease

For metastatic disease, cisplatin-based chemotherapy can allow for resection or transplantation when complete metastasectomy is achievable, albeit with inferior results 6. Salvage chemotherapy is used for recurrence 7.

Emerging therapies for chemotherapy-resistant disease include:

• Immunotherapy 1, 2
• Targeted therapies 1, 2
• Radiofrequency ablation 7
• Cyberknife treatment 7

---

Outcomes

With modern risk-based protocols and multidisciplinary management, 5-year overall survival is 88.9% and disease-free survival is 80.8% 7. For patients achieving complete resection or successful transplantation, 5-year overall survival reaches 100% 7.

Key Prognostic Factors:

• Advanced PRETEXT class: Worse outcome 6
• Histologic features: Affect prognosis 6
• Age at presentation: Influences outcome 6
• AFP production: Prognostic marker 6
• Metastatic disease: Adversely affects outcome 6

---

Critical Management Principles

Multidisciplinary team evaluation is essential, particularly for patients who may need liver transplantation 7, 8. The team should include:

• Pediatric oncologists
• Hepatobiliary surgeons
• Transplant surgeons
• Radiologists
• Pathologists

For congenital hepatoblastoma specifically, manage similarly to older children if patients are stable enough to undergo proper staging and treatment 5. Do not assume worse prognosis based solely on congenital presentation.

Maintain high clinical awareness for liver tumor development in children with metabolic syndromes causing liver damage and cirrhosis 4.